logo

Argenx Se (ARGX)



Trade ARGX now with
  Date
  Headline
8/25/2021 1:07:12 AM Argenx Announces Validation Of EMA Application For Efgartigimod In Generalized Myasthenia Gravis
5/14/2021 1:44:36 AM Argenx Q1 Loss/Shr $0.81 Vs Loss $2.06 Last Year
2/2/2021 9:41:58 AM Argenx Says Not Aware Of Any Elevation Of Cholesterol Markers Related To Treatment With Efgartigimod
12/4/2018 7:49:18 AM Wedbush Reiterates argenx SE (ARGX) At Outperform With $131 Up From $130 Price Target
11/5/2018 6:53:28 AM Wedbush Reiterates argenx SE (ARGX) At Outperform With $130 Up From $125 Price Target
9/20/2018 6:43:14 AM Wedbush Reiterates argenx SE (ARGX) At Outperform With $125 Up From $121 Price Target
9/18/2018 6:38:23 AM Wedbush Reiterates argenx SE (ARGX) At Outperform With $121 Up From $114 Price Target
5/10/2018 11:56:26 AM Wedbush Is Lowering argenx SE (ARGX) FY18 Rev. Estimate To 14.2 M From 16.1 M
5/10/2018 11:56:11 AM Wedbush Is Lowering argenx SE (ARGX) Q4 18 Rev. Estimate To 2.5 M From 3.0 M
5/10/2018 11:55:59 AM Wedbush Is Lowering argenx SE (ARGX) Q3 18 Rev. Estimate To 2.4 M From 2.9 M
5/10/2018 11:55:49 AM Wedbush Is Lowering argenx SE (ARGX) Q2 18 Rev. Estimate To 2.4 M From 2.9 M
5/10/2018 11:55:01 AM Wedbush Is Cutting argenx SE (ARGX) FY18 Estimate To -2.61 From -2.55
5/10/2018 11:54:22 AM Wedbush Is Increasing argenx SE (ARGX) Q4 18 Estimate To -0.75 From -0.77
5/10/2018 11:54:08 AM Wedbush Is Raising argenx SE (ARGX) Q3 18 Estimate To -0.68 From -0.70
5/10/2018 11:53:43 AM Wedbush Is Increasing argenx SE (ARGX) Q2 18 Estimate To -0.62 From -0.64
5/10/2018 11:53:14 AM Wedbush Reiterates argenx SE (ARGX) At Outperform With $93 Up From $92 Price Target